Amplia today announced that following the Safety Review Committee's assessment that the AMP945 dose used in Cohort 1 of the ACCENT trial was safe and well tolerated, dosing of the first patient in Cohort 2 has commenced.
Under the ACCENT trial design, patients in Cohort 2 will receive an escalated dose of AMP945 in combination with gemcitabine/nab-paclitaxel chemotherapy. The end goal of the Phase 1b stage of the trial is to identify the optimal treatment dosage of AMP945 in first-line patients with pancreatic cancer.
Amplia’s CEO and Managing Director Dr Chris Burns commented:
“Identifying a safe and well-tolerated dose of AMP945 that effectively shuts down FAK activity is a critical part of the Phase 1b arm of the ACCENT trial. Based on our extensive preclinical studies, we are hopeful that AMP945 used in conjunction with standard-of-care drugs gemcitabine/nab-paclitaxel, will improve patient outcomes. As always, we are grateful to the patients and their loved ones for consenting to take part in this trial.”
Click here to read today’s ASX release.
